FREDERICK, Md., July 27 /PRNewswire-FirstCall/ -- BioElectronics Corp. (Pink Sheets: BIEL), manufacturers of innovative pain relieving medical devices, today announced its distribution partner for Japan, YesDTC Holdings, Inc. (OTC Bulletin Board: YESD) has received notification from its legal staff of the pending review by Japanese government medical device regulators for the ActiPatch™ and Allay™ Menstrual Relief products. This review will take place on Wednesday, July 28th.
The initial analysis by YesDTC's attorneys has been very favorable toward the Company's ability to begin marketing in Japan as several similar devices are already on the market. This regulatory review is designed to verify that Japanese regulatory agencies will place ActiPatch and Allay in the same category as these currently marketed devices or if additional information and or testing will be required.
BioElectronics and YesDTC recently announced several important product line enhancements specifically tailored to suit the needs of the highly discerning and quality conscious Japanese marketplace. Additionally, upon release, BioElectronics will make the recently announced back pain belt available to the Japanese marketplace.
Andrew Whelan, CEO of BioElectronics, commented, "We view the Japanese market as being significant to our future success. There is a history of Japanese regulators closely mirroring the medical device classifications that had earlier occurred within the European Union, where we are a Class IIa device. This pending review, which will take place this week, should offer us a great deal of information about the timing in what we believe will be a highly profitable market."
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.bielcorp.com.
|SOURCE BioElectronics Corp.|
Copyright©2010 PR Newswire.
All rights reserved